# Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Canonical URL: https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-new-clinical-results-highlighting-durable-progression-free-survival-data-for-solnerstotug-in-pd-l-1-resistant-tumors-at-the-esmo-congress-2025
Ticker: SNSE
Company: Sensei Biotherapeutics
Source: Sensei Biotherapeutics
Published: 2025-10-17 12:00 EST
Original Source URL: https://investors.senseibio.com
## Summary

6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort – Favorable safety profile with six cases of mild,

## Article Body
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort – Favorable safety profile with six cases of mild,
## Recent Company News
- 2026-05-15 11:30 EST — [Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-05-05 11:30 EST — [Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-doses-first-patient-in-phase-1b-2-trial-of-piktor-in-hr-her2-advanced-breast-cancer) — Source: Sensei Biotherapeutics
- 2026-04-09 11:30 EST — [Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Sensei Biotherapeutics
- 2026-03-30 11:30 EST — [Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-03-17 10:00 EST — [Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Sensei Biotherapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)